Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes

Philip Raskin, Titus Gylvin, Wayne Weng, Louis Chaykin

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background: This treat-to-target study compared the efficacy and safety of insulin detemir (IDet) and insulin glargine (IGla) in a basal-bolus (insulin aspart) regimen in type 2 diabetes. Methods: 385 patients were randomized 2 : 1 (IDet : IGla). Non-inferiority of IDet to IGla was determined by HbA 1c 95% CI upper limit <0.4. Results: IDet and IGla showed similar efficacy in HbA1c reduction at 26 weeks, as the non-inferiority criterion was met at 26 weeks (LS mean [Det-Gla]: 0.207; 95% CI: 0.0149,0.3995). It appeared that IGla in some cases did better than IDet in terms of HbA1c, but the difference (0.207%) was not clinically meaningful. Based on the CONSORT guideline, non-inferiority analysis using the LOCF approach was inconclusive regarding possible inferiority of delta 0.4 (LS mean of [Det-Gla]: 0.307; 95% CI: 0.1023, 0.5109). HbA1c decreased significantly from baseline in IDet (-1.1% [26 weeks], -0.9% [LOCF], p < 0.001) and in IGla (-1.3% [26 weeks, LOCF], p < 0.001). Final HbA1c were 7.1% (26 weeks) and 7.3% (LOCF) in IDet, and 6.9% (26 weeks) and 7.0% (LOCF) in IGla. Final FPG were 130 mg/dL (26 weeks) and 135 mg/dL (LOCF) in IDet, and 134 mg/dL (26 weeks) and 137 mg/dL (LOCF) in IGla. There was significantly less weight gain in IDet-treated patients (1.2 ± 3.96 kg versus 2.7 ± 3.94 kg, p = 0.001). Hypoglycemia risk was comparable between groups. The majority of IDet-treated patients (87.4%) remained on a once-daily basal insulin regimen throughout the study. Conclusions: IDet and IGla were both effective and safe treatments for glycemic control in a basal-bolus regimen for type 2 diabetes. Clinically significant reductions in HbA1c were achieved in both groups, but with significantly less weight gain in the IDet group at comparable basal insulin dosage.

Original languageEnglish (US)
Pages (from-to)542-548
Number of pages7
JournalDiabetes/Metabolism Research and Reviews
Volume25
Issue number6
DOIs
StatePublished - Sep 2009

Fingerprint

Type 2 Diabetes Mellitus
Weight Gain
Insulin Detemir
Clinical Studies
Insulin Glargine
Insulin Aspart
Insulin
Hypoglycemia
Guidelines
Safety

Keywords

  • Glycemic control
  • Hypoglycemia
  • Insulin detemir
  • Insulin glargine
  • Type 2 diabetes
  • Weight gain

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. / Raskin, Philip; Gylvin, Titus; Weng, Wayne; Chaykin, Louis.

In: Diabetes/Metabolism Research and Reviews, Vol. 25, No. 6, 09.2009, p. 542-548.

Research output: Contribution to journalArticle

@article{48aa8ed9ccf84496b4ab3894163c129f,
title = "Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes",
abstract = "Background: This treat-to-target study compared the efficacy and safety of insulin detemir (IDet) and insulin glargine (IGla) in a basal-bolus (insulin aspart) regimen in type 2 diabetes. Methods: 385 patients were randomized 2 : 1 (IDet : IGla). Non-inferiority of IDet to IGla was determined by HbA 1c 95{\%} CI upper limit <0.4. Results: IDet and IGla showed similar efficacy in HbA1c reduction at 26 weeks, as the non-inferiority criterion was met at 26 weeks (LS mean [Det-Gla]: 0.207; 95{\%} CI: 0.0149,0.3995). It appeared that IGla in some cases did better than IDet in terms of HbA1c, but the difference (0.207{\%}) was not clinically meaningful. Based on the CONSORT guideline, non-inferiority analysis using the LOCF approach was inconclusive regarding possible inferiority of delta 0.4 (LS mean of [Det-Gla]: 0.307; 95{\%} CI: 0.1023, 0.5109). HbA1c decreased significantly from baseline in IDet (-1.1{\%} [26 weeks], -0.9{\%} [LOCF], p < 0.001) and in IGla (-1.3{\%} [26 weeks, LOCF], p < 0.001). Final HbA1c were 7.1{\%} (26 weeks) and 7.3{\%} (LOCF) in IDet, and 6.9{\%} (26 weeks) and 7.0{\%} (LOCF) in IGla. Final FPG were 130 mg/dL (26 weeks) and 135 mg/dL (LOCF) in IDet, and 134 mg/dL (26 weeks) and 137 mg/dL (LOCF) in IGla. There was significantly less weight gain in IDet-treated patients (1.2 ± 3.96 kg versus 2.7 ± 3.94 kg, p = 0.001). Hypoglycemia risk was comparable between groups. The majority of IDet-treated patients (87.4{\%}) remained on a once-daily basal insulin regimen throughout the study. Conclusions: IDet and IGla were both effective and safe treatments for glycemic control in a basal-bolus regimen for type 2 diabetes. Clinically significant reductions in HbA1c were achieved in both groups, but with significantly less weight gain in the IDet group at comparable basal insulin dosage.",
keywords = "Glycemic control, Hypoglycemia, Insulin detemir, Insulin glargine, Type 2 diabetes, Weight gain",
author = "Philip Raskin and Titus Gylvin and Wayne Weng and Louis Chaykin",
year = "2009",
month = "9",
doi = "10.1002/dmrr.989",
language = "English (US)",
volume = "25",
pages = "542--548",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes

AU - Raskin, Philip

AU - Gylvin, Titus

AU - Weng, Wayne

AU - Chaykin, Louis

PY - 2009/9

Y1 - 2009/9

N2 - Background: This treat-to-target study compared the efficacy and safety of insulin detemir (IDet) and insulin glargine (IGla) in a basal-bolus (insulin aspart) regimen in type 2 diabetes. Methods: 385 patients were randomized 2 : 1 (IDet : IGla). Non-inferiority of IDet to IGla was determined by HbA 1c 95% CI upper limit <0.4. Results: IDet and IGla showed similar efficacy in HbA1c reduction at 26 weeks, as the non-inferiority criterion was met at 26 weeks (LS mean [Det-Gla]: 0.207; 95% CI: 0.0149,0.3995). It appeared that IGla in some cases did better than IDet in terms of HbA1c, but the difference (0.207%) was not clinically meaningful. Based on the CONSORT guideline, non-inferiority analysis using the LOCF approach was inconclusive regarding possible inferiority of delta 0.4 (LS mean of [Det-Gla]: 0.307; 95% CI: 0.1023, 0.5109). HbA1c decreased significantly from baseline in IDet (-1.1% [26 weeks], -0.9% [LOCF], p < 0.001) and in IGla (-1.3% [26 weeks, LOCF], p < 0.001). Final HbA1c were 7.1% (26 weeks) and 7.3% (LOCF) in IDet, and 6.9% (26 weeks) and 7.0% (LOCF) in IGla. Final FPG were 130 mg/dL (26 weeks) and 135 mg/dL (LOCF) in IDet, and 134 mg/dL (26 weeks) and 137 mg/dL (LOCF) in IGla. There was significantly less weight gain in IDet-treated patients (1.2 ± 3.96 kg versus 2.7 ± 3.94 kg, p = 0.001). Hypoglycemia risk was comparable between groups. The majority of IDet-treated patients (87.4%) remained on a once-daily basal insulin regimen throughout the study. Conclusions: IDet and IGla were both effective and safe treatments for glycemic control in a basal-bolus regimen for type 2 diabetes. Clinically significant reductions in HbA1c were achieved in both groups, but with significantly less weight gain in the IDet group at comparable basal insulin dosage.

AB - Background: This treat-to-target study compared the efficacy and safety of insulin detemir (IDet) and insulin glargine (IGla) in a basal-bolus (insulin aspart) regimen in type 2 diabetes. Methods: 385 patients were randomized 2 : 1 (IDet : IGla). Non-inferiority of IDet to IGla was determined by HbA 1c 95% CI upper limit <0.4. Results: IDet and IGla showed similar efficacy in HbA1c reduction at 26 weeks, as the non-inferiority criterion was met at 26 weeks (LS mean [Det-Gla]: 0.207; 95% CI: 0.0149,0.3995). It appeared that IGla in some cases did better than IDet in terms of HbA1c, but the difference (0.207%) was not clinically meaningful. Based on the CONSORT guideline, non-inferiority analysis using the LOCF approach was inconclusive regarding possible inferiority of delta 0.4 (LS mean of [Det-Gla]: 0.307; 95% CI: 0.1023, 0.5109). HbA1c decreased significantly from baseline in IDet (-1.1% [26 weeks], -0.9% [LOCF], p < 0.001) and in IGla (-1.3% [26 weeks, LOCF], p < 0.001). Final HbA1c were 7.1% (26 weeks) and 7.3% (LOCF) in IDet, and 6.9% (26 weeks) and 7.0% (LOCF) in IGla. Final FPG were 130 mg/dL (26 weeks) and 135 mg/dL (LOCF) in IDet, and 134 mg/dL (26 weeks) and 137 mg/dL (LOCF) in IGla. There was significantly less weight gain in IDet-treated patients (1.2 ± 3.96 kg versus 2.7 ± 3.94 kg, p = 0.001). Hypoglycemia risk was comparable between groups. The majority of IDet-treated patients (87.4%) remained on a once-daily basal insulin regimen throughout the study. Conclusions: IDet and IGla were both effective and safe treatments for glycemic control in a basal-bolus regimen for type 2 diabetes. Clinically significant reductions in HbA1c were achieved in both groups, but with significantly less weight gain in the IDet group at comparable basal insulin dosage.

KW - Glycemic control

KW - Hypoglycemia

KW - Insulin detemir

KW - Insulin glargine

KW - Type 2 diabetes

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=70350605350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350605350&partnerID=8YFLogxK

U2 - 10.1002/dmrr.989

DO - 10.1002/dmrr.989

M3 - Article

C2 - 19565569

AN - SCOPUS:70350605350

VL - 25

SP - 542

EP - 548

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 6

ER -